Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED    
On or around 11/08/2018 (Date of order of final judgment)

Filing Date: November 17, 2017

Ocera Therapeutics, Inc. (“Ocera” or the Company) is a clinical-stage biopharmaceutical company targeting acute and chronic orphan liver diseases.

According to the Complaint, this action stems from a Proposed Transaction announced on November 2, 2017, pursuant to which Ocera will be acquired by affiliates of Mallinckrodt plc.

On November 1, 2017, Ocera’s Board of Directors caused the Company to enter into an agreement and plan of merger (the “Merger Agreement”) with MAK LLC (“Parent”), MEH Acquisition Co. (“Merger Sub”), and Mallinckrodt plc (together, “Mallinckrodt”). Pursuant to the terms of the Merger Agreement, Merger Sub launched a Tender Offer to acquire all of the Company’s outstanding common stock for: (i) $1.52 per share in cash, and (ii) one contingent value right per share, which represents the contractual right to receive one or more payments in cash currently estimated to be up to $2.58 in the aggregate, contingent upon the achievement of certain milestones. The Tender Offer is scheduled to expire on December 8, 2017.

On November 9, 2017, Defendants filed a Solicitation/Recommendation Statement (the “Solicitation Statement”) with the United States Securities and Exchange Commission in connection with the Proposed Transaction.

The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading. Accordingly, Plaintiff alleges herein that Defendants violated Sections 14(e), 14(d), and 20(a) of the Securities Exchange Act of 1934 in connection with the Solicitation Statement.

On February 8, 2018, Plaintiff voluntarily dismissed this case. A related case filed under Docket 17-CV-06687 in the Northern District of California continues.

On March 27, 2018, the Court issued an Order consolidating cases and appointing Co-Lead Plaintiffs and Counsel. The consolidated cases shall be identified as "In re Ocera Therapeutics, Inc. Securities Litigation." Lead Plaintiffs filed a consolidated Complaint on April 26, 2018. Defendants filed a Motion to Dismiss the consolidated Complaint on June 11. On October 16, the Court issued an Order granting Defendants' Motion to Dismiss. Lead Plaintiffs were given leave to amend the Complaint. Plaintiffs elected not to amend and the Court entered judgment in favor of the Defendants on November 8. On December 10, one of the Co-Lead Plaintiffs filed a Notice appealing the judgment in favor of Defendants and the related Order granting Defendants' Motion to Dismiss. The Court of Appeals affirmed the District Court's judgment on May 28, 2020.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.